M McClung
Overview
Explore the profile of M McClung including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
1181
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Makinen V, Solling A, McClung M, Langdahl B
J Endocrinol Invest
. 2024 Nov;
48(3):547-572.
PMID: 39487940
Introduction: Romosozumab, a new treatment of osteoporosis, is a monoclonal antibody that targets sclerostin and thereby exhibits a dual mechanism of action by stimulating bone formation and inhibiting bone resorption....
2.
Hagino H, Tanaka K, Silverman S, McClung M, Gandra S, Charokopou M, et al.
Osteoporos Int
. 2021 Mar;
32(10):2011-2021.
PMID: 33772328
Introduction: This study aims to assess the cost effectiveness of romosozumab versus teriparatide, both sequenced to alendronate, for the treatment of severe postmenopausal osteoporosis in Japanese women previously treated with...
3.
Bouxsein M, Zysset P, Gluer C, McClung M, Biver E, Pierroz D, et al.
Osteoporos Int
. 2020 Jan;
31(3):393-408.
PMID: 31900541
Introduction: The risk of hip fractures increases exponentially with age due to a progressive loss of bone mass, deterioration of bone structure, and increased incidence of falls. Areal bone mineral...
4.
Chakhtoura M, Leslie W, McClung M, Cheung A, El-Hajj Fuleihan G
Osteoporos Int
. 2016 Sep;
28(1):127-137.
PMID: 27650643
Introduction: The FRAX risk calculator is used to guide intervention thresholds in several national osteoporosis guidelines. This study aimed to describe the approach in developing FRAX-based osteoporosis treatment guidelines in...
5.
Cosman F, Gilchrist N, McClung M, Foldes J, de Villiers T, Santora A, et al.
Osteoporos Int
. 2015 Nov;
27(1):377-86.
PMID: 26556736
Unlabelled: In women with osteoporosis treated with alendronate for >12 months and oral bisphosphonates for >3 of the last 4 years, switching to MK-5442, a calcium receptor antagonist, stimulated endogenous...
6.
Barry S, Marryat L, Thompson L, Ellaway A, White J, McClung M, et al.
Child Care Health Dev
. 2015 Feb;
41(6):853-64.
PMID: 25707313
Background: Social, emotional and behavioural development in early to middle childhood impact upon many outcomes in future life and are influenced by home, neighbourhood and school environments. We used linked...
7.
Boonen S, Adachi J, Man Z, Cummings S, Lippuner K, Torring O, et al.
J Clin Endocrinol Metab
. 2011 Mar;
96(6):1727-36.
PMID: 21411557
Context: The FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months) trial showed denosumab significantly reduced the risk of fractures in postmenopausal women with osteoporosis. Objective: We evaluated...
8.
Vasikaran S, Eastell R, Bruyere O, Foldes A, Garnero P, Griesmacher A, et al.
Osteoporos Int
. 2010 Dec;
22(2):391-420.
PMID: 21184054
Unlabelled: The International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) recommend that a marker of bone formation (serum procollagen type I N propeptide,...
9.
Adami S, San Martin J, Munoz-Torres M, Econs M, Xie L, Dalsky G, et al.
Osteoporos Int
. 2007 Oct;
19(1):87-94.
PMID: 17938984
Unlabelled: Loss of bone mineral density occurs after discontinuation of teriparatide, if no subsequent treatment is given. Sequential raloxifene prevented rapid bone loss at lumbar spine and further increased bone...
10.
McClung M
Int J Clin Pract Suppl
. 2003 Apr;
101:67-72.
PMID: 12669743
Major Phase III studies were planned to address basic issues regarding the effectiveness and safety of alendronate. However, 3 special studies were designed to provide information regarding the effectiveness and...